Comparison between Datasol IPO and Goldline Pharmaceutical IPO.
Datasol IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Goldline Pharmaceutical IPO is a SME Bookbuilding proposed to list at BSE SME.
| Datasol IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Finshore Management Services Ltd. | Cumulative Capital Pvt.Ltd. |
| Registrar | Integrated Registry Management Services Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Nirman Share Brokers Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Datasol IPO is up to ₹0.00 Cr whereas the issue size of the Goldline Pharmaceutical IPO is up to ₹11.02 Cr. The final issue price of Datasol IPO is and of Goldline Pharmaceutical IPO is ₹43.00 per share.
| Datasol IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹41.00 per share | |
| Issue Price (Upper) | ₹43.00 per share | |
| Issue Price (Final) | ₹43.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 3000 shares | |
| Fresh Issue Size | 39,20,000 shares | 25,62,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹11.02 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 39,20,000 shares | 25,62,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹11.02 Cr |
Datasol IPO opens on , while Goldline Pharmaceutical IPO opens on May 12, 2026. The closing date of Datasol IPO and Goldline Pharmaceutical IPO is , and May 14, 2026, respectively.
| Datasol IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Bid Date | May 11, 2026 | |
| Issue Open | May 12, 2026 | |
| Issue Close | May 14, 2026 | |
| Basis Of Allotment (Tentative) | May 15, 2026 | |
| Initiation of Refunds (Tentative) | May 18, 2026 | |
| Credit of Share (Tentative) | May 18, 2026 | |
| Listing date (Tentative) | May 19, 2026 | |
| Anchor Lockin End date 1 | Jun 14, 2026 | |
| Anchor Lockin End date 2 | Aug 13, 2026 |
Datasol IPO P/E ratio is , as compared to Goldline Pharmaceutical IPO P/E ratio of 10.47.
| Datasol IPO | Goldline Pharmaceutical IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 90 | 79.70 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 57.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 10.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹41.28 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 21.68 | 35.83 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 27.55 | 38.45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.03 | 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 19.56 | 27.37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Datasol IPO Retail Individual Investors (RII) are offered 0 shares while in Goldline Pharmaceutical IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Datasol IPO and 5,40,000 shares in Goldline Pharmaceutical IPO.
| Datasol IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 7,32,000 shares |
| Market Maker Reservation | 0 shares | 1,38,000 shares |
| QIB | 0 shares | 5,40,000 shares |
| NII | 0 shares | 3,90,000 shares |
| RII | 0 shares | 9,00,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 25,62,000 shares |
Datasol IPO subscribed in total, whereas Goldline Pharmaceutical IPO subscribed 600.53x.
| Datasol IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| QIB (times) | 180.22x | |
| NII (times) | 1,662.04x | |
| Big NII (times) | 2,010.60x | |
| Small NII (times) | 980.75x | |
| RII (times) | 881.15x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 600.53x |
